Amphion Innovations plc Interim Results for the 6 months to 30 June 2009.LONDON & NEW YORK New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of -- Amphion Innovations plc (LSE LSE - Language Sensitive Editor : AMP) ("Amphion" or the "Company"), the developer of medical and technology businesses, today announces its unaudited interim results for the six months to 30 June 2009. Highlights * Net Asset Value per Share was approximately unchanged versus December 2008 at US $0.44, but down 15.38% since June 2008 (US $0.52). In sterling terms, the NAV See navigation system and navigation bar. per Share increased by 3.85% to 0.27 over the levels of June 2008 (0.26), a 10% decrease since December 2008 (0.30) * Operating results improved sharply from a loss of over US $1.73 million in the first half of 2008, to very close to breakeven breakeven 1. The level of output or sales necessary to cover fixed expenses. Companies in industries that have high fixed costs and, consequently, high breakevens, such as automobile and steel manufacturing, are likely to exhibit large fluctuations for the first half of 2009 * DataTern, Inc. signed 7 non-exclusive patent license agreements during the first half of 2009, with an additional license agreement concluded in July. In August, the United States Patent and Trademark Office The United States Patent and Trademark Office (PTO or USPTO) is an agency in the United States Department of Commerce that provides patent protection to inventors and businesses for their inventions, and trademark registration for product and intellectual property found DataTern's '502 patent valid for all 18 original claims and 26 new claims after re-examination. DataTern has now signed a total of 11 license agreements, bringing its total revenues since inception to approximately US $9.4 million * Received a further subscription of 716,900 bringing the total to 3.5 million for Amphion's Convertible Promissory Note promissory note, unconditional written promise to pay a certain sum of money at a definite time to bearer or to a specified person on his order. Promissory notes are generally used as evidence of debt. , launched to support funding for Amphion and the Partner Companies Amphion's Chief Executive Officer, Richard Morgan Richard Morgan may refer to the following people:
"I am pleased to announce that Amphion has managed to weather the economic and financial storm of the last six months relatively well, with a near breakeven versus the US $1.73 million operating loss operating loss The excess of operating expenses over revenue. As with operating income, operating losses exclude revenues and expenses from operations that are not considered a regular part of the business. Also called deficit. Compare operating income. for the first half of 2008. We have also made good progress in the development of our IP licensing programme through DataTern, which has established itself as a significant source of revenue for Amphion. I am excited by the value that is being created in each of our Partner Companies and remain confident in the strength of the Amphion model." Notes to editors About Amphion Innovations plc Amphion Innovations plc (LSE: AMP) builds shareholder value in high growth companies in the medical and technology sectors, by using a focused, hands-on company building approach, based on decades of experience in both the US and UK. Amphion has significant shareholding in 8 Partner Companies and two specialised entities, developing proven technologies targeting substantial commercial marketplaces, each in excess of US $1 billion. Each Partner Company is chosen with the goal of achieving an exit valuation in excess of US $100 million. On the web: www.amphionplc.com |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion